4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 110 | 111 | +1 |
| Shares | 41.9M | 42.4M | +520.1K (+1.2%) |
| Value | $533.6M | $859.8M | +$326.3M (+61.1%) |
New holders (20)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Integral Health Asset Management, LLC | 375,000 | $7.60M | 1.10% |
| Sectoral Asset Management Inc | 142,510 | $2.89M | 1.24% |
| Vontobel Holding Ltd. | 142,510 | $2.89M | 0.02% |
| Acuta Capital Partners, LLC | 74,500 | $1.51M | 0.85% |
| Laurion Capital Management LP | 52,828 | $1.07M | 0.04% |
| DekaBank Deutsche Girozentrale | 46,000 | $966.0K | 0.00% |
| Alps Advisors Inc | 29,032 | $588.2K | 0.00% |
| Bank of Montreal | 25,799 | $545.6K | 0.00% |
| Qube Research & Technologies Ltd | 21,853 | $442.7K | 0.00% |
| HSBC Holdings PLC | 18,654 | $383.9K | 0.00% |
| Royce & Associates LP | 18,769 | $380.3K | 0.00% |
| BFSG, LLC | 1,500 | $30.4K | 0.00% |
| Signaturefd, LLC | 579 | $11.7K | 0.00% |
| Lindbrook Capital, LLC | 68 | $1.38K | 0.00% |
| GAMMA Investing LLC | 56 | $966 | 0.00% |
| Parallel Advisors, LLC | 33 | $669 | 0.00% |
| The PNC Financial Services Group, Inc. | 32 | $648 | 0.00% |
| McGlone Suttner Wealth Management, Inc. | 25 | $507 | 0.00% |
| Farther Finance Advisors, LLC | 11 | $223 | 0.00% |
| Able Wealth Management LLC | 9 | $182 | 0.00% |
Sold out (19)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 650,000 | $8.27M |
| Millennium Management LLC | 331,516 | $4.22M |
| Verition Fund Management LLC | 167,137 | $2.13M |
| First Manhattan Co | 160,392 | $2.04M |
| GMT Capital Corp | 151,200 | $1.92M |
| Two Sigma Investments, LP | 101,863 | $1.30M |
| Two Sigma Advisers, LP | 87,200 | $1.11M |
| Squarepoint Ops LLC | 47,749 | $607.8K |
| Trexquant Investment LP | 44,443 | $565.8K |
| ExodusPoint Capital Management, LP | 29,307 | $373.0K |
| Dynamic Technology Lab Private Ltd | 26,330 | $335.0K |
| Ghisallo Capital Management LLC | 25,000 | $318.3K |
| Aigen Investment Management, LP | 16,985 | $216.2K |
| Fox Run Management, L.L.C. | 12,162 | $154.8K |
| Affinity Wealth Management LLC | 11,471 | $146.0K |
| Point72 Middle East FZE | 11,304 | $143.9K |
| Vident Advisory, LLC | 10,574 | $134.6K |
| Newbridge Financial Services Group, Inc. | 30 | $382 |
| Russell Investments Group, Ltd. | 16 | $204 |